- HK$380.97m
- HK$169.89m
- CNY1.62bn
Brief: Cloudr Says Co Expects FY Net Loss Between Rmb880 Million And Rmb980 Million
Brief: ClouDr Group Proposes Issue Of Convertible Bonds Under General Mandate
China's ClouDr rises to 4-month high on medical AI integration with DeepSeek-R1 model
Brief: Cloudr Announces Improvement Of Cloudr Brain Through Integration Of DeepSeek
Brief: ClouDr Group Says Zuo Yinghui Appointed As An Executive Director
Brief: Cloudr Group Says CLOUDT-01 Approved By Zhejiang Medical Products Administration Of China
Brief: ClouDr Group Enters Strategic Cooperation Agreement With Medice
Brief: ClouDr Group Posts H1 Net Income Attributable RMB -115.8 Million
Brief: Cloudr Group Announces License Agreement
Brief: Cloudr Says Application For Market Launch Of Vitamin B6 Injection Solution Filed And Accepted
Brief: ClouDr Group Posts FY Revenue Of RMB3.69 Bln
Brief: ClouDr Group Announces Launch Of Proprietary Product, Hetangjin Dapagliflozin Tablets
Brief: Cloudr Group Announces Strategic Cooperation Agreement With Unit Of CR Sanjiu
Brief: ClouDr Group Sees FY Adjusted Net Loss Between RMB65 Million And RMB78 Million
Brief: Cloudr Group Says Strategic Cooperation Agreement With Anprime Bio
Brief: Cloudr Group Notes Unusual Share Price Movement In Trading Price Shares Of Co
Brief: Cloudr Group Announces Disposal Of Equity Interest In Subsidiary
Brief: Cloudr Group Announces Intention To Conduct On-Market Share Repurchase
Brief: ClouDr Group Says Strategic Cooperation Agreement With Jinbo Bio-Pharmaceutical